Publications by authors named "Sarita Barsainya"
Article Synopsis
- Vildagliptin is a medication for type 2 diabetes available in two forms: a 50 mg immediate release (IR) taken twice daily and a new 100 mg modified release (MR) taken once daily.
- A study compared the effectiveness and tolerability of these two formulations using healthy adults, with a focus on how well they inhibit the DPP-4 enzyme.
- The results showed that both formulations are therapeutically equivalent for DPP-4 inhibition, suggesting that the once-daily MR version could improve patient adherence to treatment, although long-term safety remains to be assessed.
Background: The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects in two trials: one in malaria patients in Asia and one in volunteers with experimentally induced malaria. In this study, the hepatic safety of cipargamin given as single doses of 10 to 150 mg and 10 to 50 mg once daily for 3 days was assessed.
View Article and Find Full Text PDFBackground: Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted to assess the hepatic safety of cipargamin (hepatic safety data are reported elsewhere).
View Article and Find Full Text PDF